I-MAB (IMAB) has released an update.
I-Mab has announced a partnership with Bristol Myers Squibb to explore a new combination treatment for gastric and esophageal cancers, involving givastomig, an investigational bispecific antibody, nivolumab, and chemotherapy. The collaboration is based on promising data from a previous givastomig monotherapy study and aims to enhance anti-tumor responses in advanced-stage patients. This clinical trial could mark a significant advancement in first-line treatment options for these types of cancer.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
